{
  "data": {
    "asOf": "2026-10-30T22:26:31.888Z",
    "dedupMethod": "exact cross-registry identifier matching; probabilistic = review only",
    "byRegistry": {
      "clinicaltrials_gov": 1
    },
    "canonicalTrial": {
      "canonicalId": "NCT07681258",
      "title": "A Study of Asciminib Safety and Efficacy in Young Adults With Chronic Myeloid Leukemia in the Gulf Region",
      "scientificTitle": "ASC4Young: Real-World Study of Asciminib Safety and Efficacy in Young Adults With Chronic Myeloid Leukemia in the Gulf Region",
      "status": "not_yet_recruiting",
      "studyType": "observational",
      "phase": [],
      "conditions": [
        "Chronic Myeloid Leukemia"
      ],
      "interventions": [],
      "sponsor": {
        "name": "Novartis Pharmaceuticals",
        "type": "INDUSTRY"
      },
      "locations": [],
      "outcomes": {
        "other": [],
        "primary": [
          "Major Molecular Response (MMR) Rate in Young Adults"
        ],
        "secondary": [
          "Incidence of Adverse Events (AEs)",
          "Number of Patients by Type and Severity of AEs",
          "Incidence of AEs Leading to Dose Modifications",
          "Number of Treatment Interruptions Due to AEs",
          "Duration of Treatment Interruptions Due to AEs",
          "Time to Treatment Discontinuation due to Adverse Events (TTDAE)",
          "Proportion of Patients who Achieve an Early Molecular Response Milestone of BCR::ABL1 IS ≤ 10% After 3 Months of Treatment",
          "Proportion of Patients who Achieve an Early Molecular Response Milestone of BCR::ABL1 IS ≤ 1% After 6 Months of Treatment",
          "MMR in Patients Aged > 40 years",
          "Rate of Deep Molecular Response",
          "Number of Patients With Prior Tyrosine Kinase Inhibitor (TKI) Treatment",
          "Duration of CML at Time of Asciminib Treatment Initiation",
          "Asciminib Starting Dose",
          "Number of Patients With Dose Modifications",
          "Number of Treatment Interruptions",
          "Duration of Treatment Interruptions",
          "Number of Patients by Reasons for Treatment Interruptions and Subsequent Treatment Switching",
          "Number of Patients by Reason for Treatment Switch",
          "Number of Patients by Clinicopathological Characteristics"
        ]
      },
      "eligibility": {
        "sex": "ALL",
        "criteria": "Inclusion Criteria\n\n* Confirmed diagnosis of Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase (Ph+ CML-CP)\n* Adult patients aged ≥ 18 years at the index date (or adult as defined by applicable national regulations)\n* Documented exposure to asciminib during the identification period (May 2023 to May 2026)\n* Provision of signed informed consent for secondary use of data, or an ethics committee-approved waiver of consent, where applicable (including for deceased patients or where data were previously collected within the EHR system)\n\nExclusion Criteria\n\n* Patients who do not meet the eligibility criteria specified above\n* Patients with insufficient medical record documentation to determine asciminib exposure or key study outcomes",
        "maximumAge": "99 Years",
        "minimumAge": "18 Years",
        "healthyVolunteers": false
      },
      "enrollment": {
        "type": "ESTIMATED",
        "count": 80
      },
      "startDate": "2026-10-29",
      "completionDate": "2027-07-30",
      "lastUpdated": "2026-10-27T00:00:00.000Z",
      "firstPosted": "2026-07-02T00:00:00.000Z",
      "resultsAvailable": false,
      "sourceRegistries": [
        "clinicaltrials_gov"
      ],
      "sourceUrls": [
        "https://clinicaltrials.gov/study/NCT07681258"
      ]
    },
    "identifiers": [
      {
        "idType": "nct",
        "idValue": "NCT07681258",
        "declaredBy": "clinicaltrials_gov"
      }
    ],
    "sourceRecords": [
      {
        "registry": "clinicaltrials_gov",
        "registryName": "ClinicalTrials.gov",
        "license": "public-domain",
        "sourceId": "NCT07681258",
        "sourceUrl": "https://clinicaltrials.gov/study/NCT07681258",
        "sourceStatus": "NOT_YET_RECRUITING",
        "retrievedAt": "2026-10-28T04:32:19.272Z",
        "payloadSha256": "1849634bf9edfb89a6121efae21c88aa22ed08c53036202ad765620d2d244768",
        "piiRedacted": true
      }
    ],
    "citation": {
      "canonicalId": "NCT07681258",
      "sources": [
        {
          "registry": "clinicaltrials_gov",
          "registryName": "ClinicalTrials.gov",
          "license": "public-domain",
          "sourceId": "NCT07681258",
          "verifyAt": "https://clinicaltrials.gov/study/NCT07681258",
          "retrievedAt": "2026-10-28T04:32:19.272Z",
          "payloadSha256": "1849634bf9edfb89a6121efae21c88aa22ed08c53036202ad765620d2d244768",
          "text": "ClinicalTrials.gov, record NCT07681258 (https://clinicaltrials.gov/study/NCT07681258), retrieved 2026-10-28, licence: public-domain."
        }
      ],
      "crossRegistry": false,
      "dedupMethod": "exact cross-registry identifier matching; probabilistic = review only",
      "text": "Trial NCT07681258, registered in ClinicalTrials.gov, retrieved 2026-10-28. Verify at the source URLs listed; each retrieval is checksummed.",
      "note": "Only one registry is known to hold this trial. Absence from the others is not evidence it was not registered there."
    },
    "provenanceNote": "Personal contact fields (names, emails, phone numbers, addresses) are stripped from every stored payload. No participant-level data is collected or served."
  },
  "_meta": {
    "api": "The Last Economy Wire: World Trials API",
    "version": "1.0",
    "schemaVersion": "1",
    "correlationId": "req_7Tbn8fzUwzRv",
    "generatedAt": "2026-10-30T22:26:31.888Z",
    "documentation": "https://negativeresistance.com/embed",
    "license": "Free for any use. Attribution appreciated.",
    "degraded": false,
    "provenance": {
      "sources": [
        "clinicaltrials_gov"
      ],
      "attribution": {
        "clinicaltrials_gov": "ClinicalTrials.gov: licence: public-domain, https://clinicaltrials.gov/data-api/api-docs"
      },
      "dedupMethod": "exact cross-registry identifier matching; probabilistic = review only",
      "limitations": [],
      "provenanceEndpoint": "/api/v1/sources"
    },
    "freshness": {
      "newestEvidenceAt": null,
      "lastSyncedAt": {
        "clinicaltrials_gov": "2026-10-28T04:33:30.663Z"
      },
      "degradedSources": [],
      "worldwide": false,
      "maxAgeHours": 65.9,
      "fromCache": false
    },
    "links": {
      "discovery": "https://negativeresistance.com/api/v1",
      "openapi": "https://negativeresistance.com/api/v1/openapi.json",
      "mcp": "https://negativeresistance.com/api/v1/mcp",
      "agentCard": "https://negativeresistance.com/.well-known/agent.json",
      "aiPlugin": "https://negativeresistance.com/.well-known/ai-plugin.json",
      "sdk": "https://negativeresistance.com/api/v1/sdk",
      "status": "https://negativeresistance.com/api/v1/status",
      "provenance": "https://negativeresistance.com/api/v1/sources",
      "contract": "https://negativeresistance.com/api/v1/contract",
      "curriculum": "https://negativeresistance.com/api/v1/curriculum",
      "graph": "https://negativeresistance.com/api/v1/graph",
      "openQuestions": "https://negativeresistance.com/api/v1/open-questions",
      "scoreboard": "https://negativeresistance.com/api/v1/scoreboard",
      "findings": "https://negativeresistance.com/api/v1/findings",
      "claims": "https://negativeresistance.com/api/v1/claims",
      "threads": "https://negativeresistance.com/api/v1/threads",
      "assignment": "https://negativeresistance.com/api/v1/assignment",
      "changes": "https://negativeresistance.com/api/v1/changes",
      "hello": "https://negativeresistance.com/api/v1/hello",
      "errors": "https://negativeresistance.com/api/v1/errors",
      "webhooks": "https://negativeresistance.com/api/v1/webhooks",
      "a2a": "https://negativeresistance.com/api/v1/a2a",
      "deadEnds": "https://negativeresistance.com/api/v1/dead-ends",
      "decompositions": "https://negativeresistance.com/api/v1/decompositions",
      "rungs": "https://negativeresistance.com/api/v1/rungs",
      "methods": "https://negativeresistance.com/api/v1/methods",
      "reality": "https://negativeresistance.com/api/v1/reality",
      "council": "https://negativeresistance.com/api/v1/council",
      "calibration": "https://negativeresistance.com/api/v1/calibration",
      "freshness": "https://negativeresistance.com/api/v1/freshness",
      "mission": "https://negativeresistance.com/api/v1/mission",
      "twin": "https://negativeresistance.com/api/v1/twin",
      "twinExperiment": "https://negativeresistance.com/api/v1/twin/experiment",
      "betaCell": "https://negativeresistance.com/api/v1/twin/beta-cell",
      "patientModel": "https://negativeresistance.com/api/v1/twin/patient-model",
      "agentCardCanonical": "https://negativeresistance.com/.well-known/agent-card.json",
      "collaborate": "https://negativeresistance.com/collaborate",
      "manifesto": "https://negativeresistance.com/about",
      "documentation": "https://negativeresistance.com/embed",
      "connect": "https://negativeresistance.com/connect",
      "llmsTxt": "https://negativeresistance.com/llms.txt",
      "llmsFullTxt": "https://negativeresistance.com/llms-full.txt"
    },
    "disclaimer": "Research data from public registries and literature; not medical advice."
  }
}